Table 4 Mixed-effects model analysis for functional assessment of cancer therapy using EQ-5D in the ITT population

Week 4

0.03 (−0.01, 0.07)

0.18 (−3.24, 3.61)

P-value

0.1302

0.9167

Week 8

−0.01 (−0.05, 0.04)

−1.54 (−5.06, 1.98)

P-value

0.7570

0.3895

Week 12

0.00 (−0.04, 0.05)

−1.00 (−4.96, 2.97)

P-value

0.8730

0.6216

Week 16

0.02 (−0.03, 0.07)

−0.09 (−3.82, 3.65)

P-value

0.4325

0.9631

Week 20

0.02 (−0.03, 0.06)

0.17 (−3.74, 4.09)

P-value

0.4514

0.9301

Week 24

0.04 (−0.01, 0.08)

−0.04 (−3.92, 3.85)

P-value

0.1433

0.9851

Week 30

0.03 (−0.02, 0.08)

0.69 (−3.36, 4.73)

P-value

0.2915

0.7389

Week 36

0.02 (−0.03, 0.07)

1.94 (−2.24, 6.13)

P-value

0.4630

0.3623

Week 42

0.00 (−0.06, 0.06)

−1.56 (−5.92, 2.80)

P-value

0.9995

0.4823

Week 48

0.02 (−0.04, 0.07)

1.99 (−2.06, 6.03)

P-value

0.5601

0.3348

Week 60

0.03 (−0.03, 0.09)

1.53 (−3.05, 6.11)

P-value

0.2981

0.5128

Week 72

0.04 (−0.04, 0.11)

−0.97 (−6.41, 4.48)

P-value

0.3131

0.7275

Week 84

−0.04 (− 0.11, 0.02)

0.03 (−6.14, 6.20)

P-value

0.2039

0.9921